

Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Our vision is to bring forward the day when all cancers are cured. Precision medicine is increasingly recognised as the future of cancer therapy. Our Stratified Medicine Programme is a partnership with industry (AstraZeneca, Pfizer and Illumina), clinical teams, molecular diagnostic laboratories, clinical trials units and the research community. The programme is embedding a large, multi-aberration Next Generation Sequencing panel within the NHS. This information will be used to inform patient decisions through a pioneering national clinical trial for patients with advanced lung cancer - the National Lung Matrix Trial led by the Birmingham CRCTU. http://www.cancerresearchuk.org/
Congenica is a leading clinical genomics company pioneering genome based medicine. Congenica have an integrated, comprehensive and trusted platform for genome based medicine, founded on pioneering work from the Wellcome Trust Sanger Institute, NHS clinicians and genetic testing laboratories. Congenica’s lead product, SAPIENTIA, is capable of detecting complex mutations, expertly filtering clinically relevant variants and deep clinical phenotyping, combined with secure storage, and intuitive functionality to integrate, interrogate and share data. Congenica remains at the cutting edge of the constantly evolving field of precision medicine thanks to its unparalleled access to world class developments and know-how arising from the Wellcome Trust Sanger Institute. Congenica’s technology has been validated by Genomics England, and is being used in leading Genetics Service Laboratories. http://congenica.com/
Oncompass is a health information company that develops information technology methods and systems for the clinical interpretation of the molecular genetic alterations in cancer, works together with oncologists to evaluate treatment options, helps patients to get access to novel therapies and clinical trials. Oncompass works together with oncology centers, molecular diagnostics providers and clinical trials. http://www.oncompassmedicine.com/
Genomic Health is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions. http://www.genomichealth.com/
Oracle is the leading strategic software solutions provider to the health sciences industry. Oracle's comprehensive industry solutions include clinical trial management/analysis, electronic data capture, adverse event reporting / pharmacovigilance, and healthcare interoperability. Oracle partners with health sciences industry leaders to prevent and cure disease, enhance quality of life, and accelerate insights for better health. http://www.oracle.com/us/industries/health-sciences/overview/index.html
Oxford Nanopore Technologies® is developing a new generation of nanopore-based electronic systems for analysis of single molecules, including DNA, RNA and proteins. The MinION™ device, the PromethION™ and GridION™ systems are designed to provide novel qualities in molecular sensing such as real-time data streaming, improved simplicity, efficiency and scalability of workflows and direct analysis of the molecule of interest. The devices may be used in scientific research, personalised medicine, crop science, security and defence and environmental applications. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores. https://www.nanoporetech.com/
The Irys platform from BioNano Genomics provides unprecedented insights into whole-genome biology. Genome maps are generated from massively parallel single-molecule visualization of extremely long DNA, providing long-range contiguity critical for de novo sequence scaffolding and analysis of structural variation in complex genomes. These maps provide dense genome-wide anchor points for ordering and orienting sequencing contigs or scaffolds to greatly increase completion and accuracy of de novo assemblies. Structural variants and repeats are measured directly within long “reads” for comprehensive analysis of what has been referred to as the inaccessible genome. For more see http://www.bionanogenomics.com/
Seven Bridges Genomics gives people the tools they need to make sense of the world's biological information. The Seven Bridges Platform provides an integrated environment to manage, execute, and collaborate on all aspects of the NGS analysis workflow—from sample and metadata management to secondary analysis workflows to annotation and visualization. https://www.sbgenomics.com/
The UK Pharmacogenetics and Stratified Medicine Network is a research network whose main aim is to develop collaborations between academics, clinicians and industry partners, with the purpose of catalysing research opportunities within the fast growing field of stratified medicine. http://www.uk-pgx-stratmed.co.uk/
EPEMED is a pioneering and independent voice whose vision is to make Personalised Medicine and Diagnostic a reality for European patients. The organisation is a catalyst who acts for advancing personalised medicine in Europe and the breakthrough role of diagnostics and associated drug-companion diagnostics technologies in improving patient outcomes. It is a central point of communication and coordinated actions that accelerates broader adoption of personalised medicine and advanced diagnostics, and access to these treatments by patients across Europe. It comprises a dynamic and broad group of leaders, from industry (including diagnostic, pharmaceutical and device sectors), academia, research, patient groups and professional service firms, who have extensive expertise in the application and development of diagnostic tools and stratified medicines. For more information, visit http://www.epemed.org/